Sarepta Therapeutics has ceased shipments of its Duchenne muscular dystrophy gene therapy Elevidys for non-ambulatory patients following a second fatality due to acute liver failure. Both deaths involved patients with advanced disease relying on wheelchairs. Sarepta is collaborating with experts to enhance immunosuppressive regimens and plans discussions with the FDA to improve safety for these patients.